174 related articles for article (PubMed ID: 38233885)
1. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.
Aggarwal R; Schessl J; Charles-Schoeman C; Bata-Csörgő Z; Dimachkie MM; Griger Z; Moiseev S; Oddis CV; Schiopu E; Vencovský J; Beckmann I; Clodi E; Levine T;
Arthritis Res Ther; 2024 Jan; 26(1):27. PubMed ID: 38233885
[TBL] [Abstract][Full Text] [Related]
2. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study").
Aggarwal R; Charles-Schoeman C; Schessl J; Dimachkie MM; Beckmann I; Levine T
Medicine (Baltimore); 2021 Jan; 100(1):e23677. PubMed ID: 33429735
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a post-hoc analysis of the ProDERM study.
Werth VP; Aggarwal R; Charles-Schoeman C; Schessl J; Levine T; Kopasz N; Worm M; Bata-Csörgő Z
EClinicalMedicine; 2023 Oct; 64():102234. PubMed ID: 37799613
[TBL] [Abstract][Full Text] [Related]
4. Trial of Intravenous Immune Globulin in Dermatomyositis.
Aggarwal R; Charles-Schoeman C; Schessl J; Bata-Csörgő Z; Dimachkie MM; Griger Z; Moiseev S; Oddis C; Schiopu E; Vencovský J; Beckmann I; Clodi E; Bugrova O; Dankó K; Ernste F; Goyal NA; Heuer M; Hudson M; Hussain YM; Karam C; Magnolo N; Nelson R; Pozur N; Prystupa L; Sárdy M; Valenzuela G; van der Kooi AJ; Vu T; Worm M; Levine T;
N Engl J Med; 2022 Oct; 387(14):1264-1278. PubMed ID: 36198179
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study.
Cornblath DR; van Doorn PA; Hartung HP; Merkies ISJ; Katzberg HD; Hinterberger D; Clodi E;
Drug Saf; 2023 Sep; 46(9):835-845. PubMed ID: 37378806
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
8. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).
Lennox B; Yeeles K; Jones PB; Zandi M; Joyce E; Yu LM; Tomei G; Pollard R; Vincent SA; Shimazaki M; Cairns I; Dowling F; Kabir T; Barnes TRE; Lingford Hughes A; Hosseini AA; Harrower T; Buckley C; Coles A
Trials; 2019 Jun; 20(1):331. PubMed ID: 31174586
[TBL] [Abstract][Full Text] [Related]
12. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial.
Miyasaka N; Hara M; Koike T; Saito E; Yamada M; Tanaka Y;
Mod Rheumatol; 2012 Jun; 22(3):382-93. PubMed ID: 21971943
[TBL] [Abstract][Full Text] [Related]
14. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD;
Lancet Respir Med; 2019 Nov; 7(11):951-963. PubMed ID: 31582358
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of IV immunoglobulin for Alzheimer disease.
Relkin NR; Thomas RG; Rissman RA; Brewer JB; Rafii MS; van Dyck CH; Jack CR; Sano M; Knopman DS; Raman R; Szabo P; Gelmont DM; Fritsch S; Aisen PS;
Neurology; 2017 May; 88(18):1768-1775. PubMed ID: 28381506
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
Cochrane Database Syst Rev; 2013 Dec; (12):CD001797. PubMed ID: 24379104
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Hill M; Iro M; Sadarangani M; Absoud M; Cantrell L; Chong K; Clark C; Easton A; Gray V; Kneen R; Lim M; Liu X; Pike M; Solomon T; Vincent A; Willis L; Yu LM; Pollard AJ;
BMJ Open; 2023 Nov; 13(11):e072134. PubMed ID: 37945292
[TBL] [Abstract][Full Text] [Related]
20. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
